Chronic Psychiatric Disorder, Schizophrenia
Conditions
Brief summary
As in the general population, there is a gradual and steady increase in life expectancy of patients with schizophrenia. But this increase is at a smaller scale, with a rate of premature death that is still 2 to 3 times higher than that found in the general population. This excessive early mortality is explained by an overrepresentation of suicide deaths, but also a higher prevalence of somatic diseases, mainly cardiovascular. But today there are only very few epidemiological data on the mortality of patients with schizophrenia, including those aged over 60 years. What are the sociodemographic and clinical characteristics (psychiatric and somatic) of these schizophrenic elderly patients? Do they benefit from a somatic follow-up adequate and systematic? What are their levels of social independence and of quality of life? the answers these questions and the description of the offer of geriatric care and of psychiatric care currently provided by different sectors of psychiatry in France is an indispensable prerequisite for any project to improve the quality of life, state of health and mortality of older patients with schizophrenia.
Detailed description
Evaluate prospectively over 5 years, the rates and causes of mortality in a cohort of schizophrenic patients older than 60 years, followed by adult psychiatry sectors, compared to those patients matched for sex and age and monitored by the same sectors for a chronic psychiatric disorder other than schizophrenia
Interventions
OTHERData collection
Sponsors
CHU de Reims
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men or women aged than 60 years with a diagnosis of schizophrenia, according to the DSM-IV criteria * Men or women aged than 60 years with chronic psychiatric disorder other than schizophrenia * Patients consenting to participate to the study * Patients enrolled in the national healthcare insurance program
Exclusion criteria
-Disease affecting the central nervous system
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Death | 5 years | Death of any causes |
Countries
France
Outcome results
None listed